secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001842952-23-000004
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics highlights 2023 priorities: CTIM-76 candidate, ONA-XR data updates, cash runway into Q1 2024
--------------------------------------------------------------------------------

- CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody candidate; IND filing expected Q1 2024.
- ONA-XR Phase 2 endometrial cancer (OATH) shows 77% 4-month PFS rate; additional data expected mid-2023.
- ONA-XR Phase 2 breast cancer (SMILE) shows 44% 4-month PFS rate; additional data expected Q4 2023.
- ELONA Phase 1b/2 breast cancer trial with Menarini's elacestrant opened and enrolled first patient.
- Cash and equivalents $39.4M as of Sep 30, 2022; expected to fund operations into Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000004/0001842952-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000004/cntx-20230104.htm
  HTML page:      https://secwatch.observer/filing/0001842952-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer